These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 27492707)

  • 21. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
    Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
    Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
    Eichner R; Heider M; Fernández-Sáiz V; van Bebber F; Garz AK; Lemeer S; Rudelius M; Targosz BS; Jacobs L; Knorn AM; Slawska J; Platzbecker U; Germing U; Langer C; Knop S; Einsele H; Peschel C; Haass C; Keller U; Schmid B; Götze KS; Kuster B; Bassermann F
    Nat Med; 2016 Jul; 22(7):735-43. PubMed ID: 27294876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
    Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
    Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
    Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Thalidomide, cereblon and multiple myeloma].
    Ogura T
    Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
    Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
    Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
    Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
    Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
    Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
    Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
    Zhu YX; Kortuem KM; Stewart AK
    Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
    Shah SR; Tran TM
    Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
    Maier SK; Hammond JM
    Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review].
    Fan WJ; Fan ZQ; Yang MJ; Pan YZ; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1240-1243. PubMed ID: 30111438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zeroing in on cereblon.
    Heaney ML
    Eur J Haematol; 2015 Jul; 95(1):1-2. PubMed ID: 25777766
    [No Abstract]   [Full Text] [Related]  

  • 35. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
    Nguyen TV; Li J; Lu CJ; Mamrosh JL; Lu G; Cathers BE; Deshaies RJ
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3565-3571. PubMed ID: 28320958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. UBE2G1 governs the destruction of cereblon neomorphic substrates.
    Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M
    Elife; 2018 Sep; 7():. PubMed ID: 30234487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
    Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
    J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.